Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Samples that fulfill all of the criteria will be evaluated for the study.~* Samples of women aged greater than or equal to (\>/=) 18 and less than (\<) 75 years~* Tumor samples already diagnosed based on the IHC score of 0 to +3~* Samples of primary lesions excluding lymph nodes~* 10 percent (%) neutral buffered formalin-fixed and paraffin embedded tissue samples~Exclusion Criteria:~Samples that fulfill any of the criteria below will not be included in the study.~* Non-invasive ductal carcinoma (NOS) samples~* Tru-cut biopsies~* Non-breast cancer pathological samples

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Breast Cancer Pathology Samples (Type: None): Breast cancer pathology samples were evaluated for a period of 70 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).